TY - JOUR
T1 - Intermittent high permeability hemofiltration in septic patients with acute renal failure
AU - Morgera, Stanislao
AU - Rocktäschel, Jens
AU - Haase, Michael
AU - Lehmann, Christian
AU - Von Heymann, Christian
AU - Ziemer, Sabine
AU - Priem, Friedrich
AU - Hocher, Berthold
AU - Göhl, Hermann
AU - Kox, Wolfgang J.
AU - Buder, Hans W.
AU - Neumayer, Hans H.
PY - 2003/11
Y1 - 2003/11
N2 - Objective: High permeability hemofiltration (HP-HF) is a new renal replacement modality designed to facilitate the elimination of cytokines in sepsis. Clinical safety data on this new procedure is still lacking. This study investigates the effects of HP-HF on the protein and coagulation status as well as on cardiovascular hemodynamics in patients with septic shock. In addition, the clearance capacity for interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) is analyzed. Design: Prospective, single-center pilot trial. Setting: University hospital. Patients: Sixteen patients with multiple organ failure (MOF) induced by septic shock were studied. Intervention: Patients were treated by intermittent high permeability hemofiltration (iHP-HF; nominal cut-off point: 60 kilodaltons). Intermittent HP-HF was performed over 5 days for 12 h per day and alternated with conventional hemofiltration. Measurements and results: Intermittent HP-HF proved to be a safe hemofiltration modality in regard to cardiovascular hemodynamics and its impact on the coagulation status. However, transmembrane protein loss occurred and cumulative 12-h protein loss was 7.60 g (IQR: 6.2-12.0). The filtration capacity for IL-6 was exceptionally high. The IL-6 sieving coefficient approximated 1 throughout the study period. The total plasma IL-6 burden, estimated by area under curve analysis, declined over time (p<0.001 vs baseline). The TNF-α elimination capacity was poor. Conclusions: High permeability hemofiltration is a new approach in the adjuvant therapy of sepsis that facilitates the elimination of cytokines. HP-HF alternating with conventional hemofiltration is well tolerated. Further studies are needed to analyze whether HP-HF is able to mitigate the course of sepsis.
AB - Objective: High permeability hemofiltration (HP-HF) is a new renal replacement modality designed to facilitate the elimination of cytokines in sepsis. Clinical safety data on this new procedure is still lacking. This study investigates the effects of HP-HF on the protein and coagulation status as well as on cardiovascular hemodynamics in patients with septic shock. In addition, the clearance capacity for interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) is analyzed. Design: Prospective, single-center pilot trial. Setting: University hospital. Patients: Sixteen patients with multiple organ failure (MOF) induced by septic shock were studied. Intervention: Patients were treated by intermittent high permeability hemofiltration (iHP-HF; nominal cut-off point: 60 kilodaltons). Intermittent HP-HF was performed over 5 days for 12 h per day and alternated with conventional hemofiltration. Measurements and results: Intermittent HP-HF proved to be a safe hemofiltration modality in regard to cardiovascular hemodynamics and its impact on the coagulation status. However, transmembrane protein loss occurred and cumulative 12-h protein loss was 7.60 g (IQR: 6.2-12.0). The filtration capacity for IL-6 was exceptionally high. The IL-6 sieving coefficient approximated 1 throughout the study period. The total plasma IL-6 burden, estimated by area under curve analysis, declined over time (p<0.001 vs baseline). The TNF-α elimination capacity was poor. Conclusions: High permeability hemofiltration is a new approach in the adjuvant therapy of sepsis that facilitates the elimination of cytokines. HP-HF alternating with conventional hemofiltration is well tolerated. Further studies are needed to analyze whether HP-HF is able to mitigate the course of sepsis.
UR - http://www.scopus.com/inward/record.url?scp=10744233127&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744233127&partnerID=8YFLogxK
U2 - 10.1007/s00134-003-2003-9
DO - 10.1007/s00134-003-2003-9
M3 - Article
C2 - 12955174
AN - SCOPUS:10744233127
SN - 0342-4642
VL - 29
SP - 1989
EP - 1995
JO - Intensive Care Medicine
JF - Intensive Care Medicine
IS - 11
ER -